Renal cell carcinoma: today's targeted therapies improving tomorrow's outcomes.
Biedrzycki
Barbara A
BA
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000175:diagnosis / Q000628:therapy*; D018572:Disease-Free Survival; D016503:Drug Delivery Systems; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D017567:Karnofsky Performance Status; D007680:Kidney Neoplasms / Q000175:diagnosis / Q000628:therapy*; D009367:Neoplasm Staging; D009392:Nephrectomy; D009536:Niacinamide / Q000031:analogs & derivatives; D024802:Nurse's Role; D009859:Oncology Nursing / Q000458:organization & administration; D010353:Patient Education as Topic; D010671:Phenylurea Compounds; D011379:Prognosis; D011725:Pyridines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D018570:Risk Assessment; D017751:Safety Management; D000077157:Sorafenib; D000077210:Sunitinib; D016019:Survival Analysis
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D007211:Indoles; D007376:Interleukin-2; D010671:Phenylurea Compounds; D011725:Pyridines; D011758:Pyrroles; D009536:Niacinamide; D000077157:Sorafenib; D000077210:Sunitinib